European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals' Ondexxya™ (andexanet alfa), the First and Only Antidote for the ...
Sunday 28 April 2019
European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals' Ondexxya™ (andexanet alfa), the First and Only Antidote for the Reversal of Factor Xa Inhibitors | Small Molecules | News Channels - PipelineReview.com
European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals' Ondexxya™ (andexanet alfa), the First and Only Antidote for the Reversal of Factor Xa Inhibitors | Small Molecules | News Channels PipelineReview.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment